Magnetic Particle Imaging (MPI) Interest Group

mpi-banner-02
Magnetic Particle Imaging (MPI) offers scientists and clinicians the first new platform for screening, diagnosing, staging and treatment of cancer since the introduction of MRI 1980s. MPI sees superparamagnetic iron oxide (SPIO) nanoparticles by detecting the unique signature of their non-linear response to low frequency (25 kHz) magnetic fields. Background tissue is both transparent and generates no detectable MPI signal; hence MPI has contrast to background rivaling nuclear medicine and PET. This high-contrast tracer imaging enables simultaneous real-time assessment of quantitative perfusion in cancers, therapeutic cell tracking and imaging of targeted nanoparticles. MPI does not use radiation and the SPIO tracers used in MPI have proven and significant safety advantages over Iodine used in CTA and Gadolinium used in MRI.
Our goal is to establish MPI as a pre-clinical in vivo imaging technique to enable entry of this new technology into clinical practice. MPI has advantages that could benefit pre-clinical and clinical cancer imaging. We propose the following advance the implementation of magnetic particle imaging as well as the development of new tracers for vascular, cell and targeting applications:

  • Increase and advance the dialogue and cooperation between medical scientists and engineers to better align the technology evolution with relevant translational needs;
  • Provide leadership for establishing international cooperation to advance knowledge transfer and education where needed;
  • Take an advocacy position within the WMIS on issues of funding for interdisciplinary research projects to identify and develop new applications leveraging magnetic particle imaging for diagnostics and therapy development;
  • Develop translational approaches with magnetic particle imaging for clinical implementation through the involvement of regulatory, clinical and reimbursement representatives.

Our mission is aligned with the WMIS goal of accelerating the global growth of molecular imaging in academic institutions and industry.

WMIS invites you to find your place to grow, collaborate and make a difference – join the MPI Interest Group today.

Members: Interest Groups are open to current WMIS Members. There is an annual Interest Group membership fee of $20 which is requested to help offset administrative costs. To join an interest group, please click the button below.

If you are not a current WMIS member, please click the button below and create a new profile to join WMIS and join interest groups.

Membership-join-Button

Mission Statement

Our goal is to establish MPI as a pre-clinical in vivo imaging technique to enable entry of this new technology into clinical practice. MPI has advantages that could benefit pre-clinical and clinical cancer imaging. We propose the following advance the implementation of magnetic particle imaging as well as the development of new tracers for vascular, cell and targeting applications:

• Increase and advance the dialogue and cooperation between medical scientists and engineers to better align the technology evolution with relevant translational needs;

• Provide leadership for establishing international cooperation to advance knowledge transfer and education where needed;

• Take an advocacy position within the WMIS on issues of funding for interdisciplinary research projects to identify and develop new applications leveraging magnetic particle imaging for diagnostics and therapy development;

• Develop translational approaches with magnetic particle imaging for clinical implementation through the involvement of regulatory, clinical and reimbursement representatives.